IN8BIO, Inc. (INAB) intrinsic value & 10-year financials
IN8BIO, Inc. (INAB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.11
- Market cap
- $4.9M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -270.2%
- Free cash flow (FY2025)
- —
INAB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$19.4M | -$4.44 | — | — | -443.3% |
| FY2024 | — | -$30.4M | -$0.57 | — | — | -441.9% |
| FY2023 | — | -$30.0M | -$1.00 | — | — | -377.6% |
| FY2022 | — | -$28.5M | -$1.36 | — | — | -476.1% |
| FY2021 | — | -$14.7M | -$1.47 | — | — | 92.7% |
| FY2020 | — | -$8.6M | — | — | — | 24.8% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
IN8BIO, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
IN8BIO, INC. has earned high returns on invested capital, averaging 16.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
IN8BIO, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
IN8BIO, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.